Biochemistry, Heme Synthesis

Fundamentals

Heme is synthesized through a tightly regulated, multistep pathway spanning both the mitochondria and cytosol. Initial and terminal steps of the pathway occur in the mitochondria, whereas intermediate steps take place in the cytosol. In addition to de novo synthesis, cellular heme levels are maintained through intestinal absorption of dietary heme and intercellular transport mechanisms, contributing to systemic heme homeostasis.

Heme functions as a critical prosthetic group in numerous essential proteins. One of the most prominent roles occurs in hemoglobin, where oxygen transport in erythrocytes is facilitated. Additional major hemoproteins include myoglobin (oxygen storage in muscle), cytochromes (electron transport and oxidative phosphorylation), catalase and peroxidases (reactive oxygen species detoxification), and nitric oxide synthase (cell signaling and vascular regulation).

Several structurally distinct forms of heme have been identified, each adapted to specific protein environments. The most abundant form, heme B (protoheme IX), is present in hemoglobin and serves as the precursor for other heme derivatives. Heme A is a modified form present in cytochrome c oxidase (complex IV), whereas heme c is covalently bound to cytochrome c. These specialized heme types are essential for efficient oxidative phosphorylation and ETC function.[3]

The rate-limiting step of heme synthesis is catalyzed by 5′-aminolevulinic acid synthase (ALA synthase, ALAS), which condenses glycine and succinyl-CoA to form δ-aminolevulinic acid (ALA). Pyridoxal phosphate (vitamin B6) functions as a cofactor for this reaction, representing the principal regulatory point of the pathway. Two isoforms of ALAS exist, ALAS1 and ALAS2, each expressed in distinct tissues and regulated by different mechanisms. ALAS1 is a ubiquitous, hepatic mitochondrial isoform regulated primarily by negative feedback inhibition from heme. ALAS2 is an erythroid-specific mitochondrial isoform expressed in developing red blood cells and regulated at the translational level by iron availability, ensuring coordination between heme synthesis and hemoglobin production. The ALAS2 gene is located on the X chromosome, a feature with clinical relevance in X-linked sideroblastic anemia, a disorder characterized by defective heme synthesis secondary to impaired ALAS2 function.[4]

Cellular Level

Porphyrin synthesis is the biochemical process responsible for heme production. The pathway occurs in both the mitochondria and cytosol and consists of 8 enzymatic steps. Heme biosynthesis begins in the mitochondria with the condensation of succinyl-CoA, derived from the citric acid cycle, and glycine to form the key intermediate ALA. This reaction is catalyzed by ALAS, a pyridoxal phosphate–dependent enzyme.[5] This reaction is the rate-limiting and regulatory step of heme synthesis.[6]

ALA molecules formed in the mitochondria are transported into the cytosol, where condensation of 2 ALA molecules produces porphobilinogen (PBG). This reaction is catalyzed by ALA dehydratase, also known as PBG synthase, a zinc-dependent enzyme. The subsequent step involves condensation of 4 PBG molecules to form the linear tetrapyrrole hydroxymethylbilane (HMB), catalyzed by PBG deaminase, also known as HMB synthase.

Cyclization of HMB produces uroporphyrinogen III, a reaction catalyzed by uroporphyrinogen-III synthase. This step is essential, as failure to form the correct isomer results in accumulation of nonphysiologic porphyrins associated with porphyrias. Following synthesis, coproporphyrinogen III is transported back into the mitochondria, where conversion to protoporphyrinogen IX occurs via coproporphyrinogen oxidase. Protoporphyrinogen IX is subsequently oxidized to protoporphyrin IX by protoporphyrinogen oxidase.[7] In the final step, insertion of ferrous iron into protoporphyrin IX is catalyzed by ferrochelatase, resulting in heme formation.[8][9]

Molecular Level

Heme consists of ferrous iron coordinated within protoporphyrin IX, a tetrapyrrole structure composed of 4 pyrrole rings linked by methenyl bridges. In heme B, side chains are arranged around the ring in a specific order—methyl, vinyl, methyl, propionate—with this pattern repeating asymmetrically across the tetrapyrrole structure.

The central ferrous iron exhibits reversible ligand binding, most notably oxygen binding, which underlies the functional role of heme in hemoglobin and myoglobin. Chemical properties of the porphyrin ring, together with the surrounding protein environment, determine ligand affinity and specificity.

At the molecular level, heme exerts an important regulatory function in gene expression and enzyme activity, particularly through feedback inhibition of ALAS (ALAS1) in hepatocytes. Incorporation of iron into protoporphyrin IX by ferrochelatase is essential for heme formation, as disruption of this step (for example, in lead toxicity cases) impairs heme synthesis and results in the accumulation of upstream intermediates.

Function

Heme serves a variety of biological functions as a prosthetic group and cofactor. Heme facilitates oxygen transport in hemoglobin and oxygen storage in myoglobin. The molecule functions as a prosthetic group for CYP450 enzymes and acts as an intracellular reservoir of iron. Within the ETC, heme-containing proteins act as electron shuttles essential for cellular respiration. Heme also participates in signal transduction pathways, including regulation of antioxidant responses, circadian rhythm modulation, and microRNA processing. Heme also plays a role in cellular differentiation and proliferation.

Mechanism

Heme synthesis is differentially regulated in erythroid cells and hepatocytes. This differential regulation reflects distinct functional demands.

In erythroid cells, heme synthesis occurs primarily for incorporation into hemoglobin. Heme promotes globin chain synthesis in developing erythroblasts and reticulocytes, ensuring coordinated production of hemoglobin. Erythropoietin, released by the kidney in response to hypoxia, stimulates erythropoiesis and indirectly enhances heme synthesis. Accumulation of heme within erythroid precursors is required for erythroblast maturation. Regulation in these cells depends largely on intracellular iron availability, which controls the translation of the erythroid-specific enzyme ALAS2. Following terminal differentiation, red blood cells no longer exhibit active heme or hemoglobin synthesis.

In the liver, heme synthesis is more variable and tightly regulated due to the potential toxicity of free heme. Hepatocytes primarily utilize heme for the synthesis of CYP450 enzymes involved in drug metabolism. The hepatic isoform ALAS1 is subject to negative feedback regulation by intracellular heme levels. Decreased intracellular heme concentrations relieve negative feedback on ALAS1, resulting in increased transcription and enzyme activity. Increased demand for CYP450 enzymes, such as that induced by enzyme-inducing drugs, upregulates ALAS1 expression to meet increased heme requirements.

Hemin (oxidized heme) exerts negative feedback on heme synthesis by suppressing ALAS1 through multiple mechanisms. Suppression mechanisms include reduction of ALAS1 gene transcription, destabilization of ALAS1 mRNA, and inhibition of mitochondrial import of ALAS1. These mechanisms ensure tight control of hepatic heme levels and prevent toxic accumulation.

Pathophysiology

Disruptions in the regulation and enzymatic steps of heme synthesis produce a spectrum of clinically significant disorders. Mutation of ALAS2 causes X-linked sideroblastic anemia, characterized by impaired protoporphyrin production and reduced heme synthesis. Iron continues to be transported into developing erythroblasts despite this defect, resulting in mitochondrial iron accumulation and formation of ring sideroblasts.[10]

Abnormalities in downstream enzymes also impair normal porphyrin formation. During heme biosynthesis, the intermediate HMB requires enzymatic conversion to uroporphyrinogen III via uroporphyrinogen III synthase. In the absence of this enzyme, HMB undergoes spontaneous cyclization to form uroporphyrinogen I, which is subsequently converted to coproporphyrinogen I. These compounds are nonphysiologic intermediates and cannot be utilized for heme synthesis, leading to accumulation and contributing to the development of porphyrias.

Clinical Significance

Enzyme deficiencies or impaired substrate availability disrupt heme synthesis, resulting in the accumulation of toxic intermediates in blood, tissues, and urine. This process leads to a group of disorders known as porphyrias (see Image. Enzymatic Steps of Heme Synthesis and Related Porphyrias). These disorders are broadly classified as hepatic or erythropoietic and may present as acute (neurovisceral) or chronic (cutaneous) syndromes. Clinically, porphyrias are characterized by neurovisceral symptoms (eg, abdominal pain, neuropathy, psychiatric disturbances) or photosensitivity, depending on the location of the enzymatic defect. Abnormalities occurring after the formation of HMB lead to the accumulation of porphyrinogens associated with photosensitivity, whereas earlier defects typically present with neurovisceral symptoms.[11] Common features across porphyrias include abdominal pain, tachycardia, hypertension, nausea, confusion, and changes in urine color.

Acute intermittent porphyria results from a deficiency of HMB synthase, leading to the accumulation of ALA and PBG.[12] Clinical presentation includes severe abdominal pain, neuropsychiatric symptoms (eg, irritability, insomnia), tachycardia, and hypertension, without photosensitivity. Urine may darken upon exposure to air due to oxidation of accumulated intermediates.[13] Laboratory findings typically demonstrate elevated urinary PBG levels, with urine darkening upon exposure to air and sunlight. Photosensitivity is absent in acute intermittent porphyria.

Porphyria cutanea tarda, the most common porphyria, results from decreased activity of uroporphyrinogen decarboxylase and may be acquired or inherited. Accumulation of uroporphyrins causes photosensitivity, leading to blistering lesions, hyperpigmentation, and potential hepatic dysfunction. Management includes sunlight avoidance, phlebotomy, and low-dose hydroxychloroquine therapy.

Erythropoietic porphyria (eg, due to ferrochelatase deficiency) is characterized by the accumulation of protoporphyrin IX in erythrocytes. Clinical presentation includes painful photosensitivity with burning, swelling, and itching of sun-exposed skin, with potential progression to hepatic involvement.

Lead poisoning disrupts heme synthesis through the inhibition of ALA dehydratase and ferrochelatase, enzymes dependent on metal cofactors. Inhibition results in the accumulation of ALA and protoporphyrin IX, producing abdominal pain, irritability, fatigue, and neurodevelopmental impairment in children.[14]